NOVEL DRUGS AND DEVICES TO LOWER INTRAOCULAR PRESSURE MARKET ANALYSIS

Novel Drugs And Devices To Lower Intraocular Pressure MarketSize and Trends

Global Novel Drugs and Devices to Lower Intraocular Pressure Market Drivers

Approvals of drugs and devices associated with the treatment of glaucoma from regulatory bodies is expected to boost the global novel drugs and devices to lower intraocular pressure market growth. For instance, in May 2019, Ivantis Inc., received an approval from the U.S. Food and Drug Administration (FDA) for Hydrus microstent. It is a device used in minimally invasive glaucoma surgery. It is developed to lower eye pressure in patients with open angle glaucoma.

Furthermore, in September 2018, Sun Pharmaceuticals Industries Ltd. received an approval from U.S. FDA for Xelpros (latanoprost ophthalmic emulsion) for treatment of glaucoma. It reduces the elevated intraocular pressure in the eye and has been designed with the help of Swollen Micelle Micro emulsion technology. Frequent approvals of drugs and devices is expected to accelerate global novel drugs and devices to lower intraocular pressure market growth.

Key players are focused on monitoring post marketing results of approved drugs and devices for the treatment of glaucoma (Intraocular pressure), which is expected to drive the global novel drugs and devices to lower intraocular pressure market growth. For instance, Rhopressa drug manufactured by Aerie Pharmaceuticals was originally approved in December 2017 by U.S. Food and Drug Administration (FDA). The company is now studying the Rhopressa drug (Netarsudil ophthalmic solution) for its pharmacovigilance studies. The drug is being studied for its long-term effects on patients with open angle glaucoma and ocular hypertension. The study is expected to be completed by September 2019. Such developments are expected to drive the global novel drugs and devices to lower intraocular pressure market growth.